Modification-specific antibodies were used to characterize the phosphorylation and acetylation of human p53 in response to genotoxic (UV, IR, and adriamycin) and non-genotoxic (PALA, taxol, nocodazole) stress in cultured human cells at 14 known modification sites. In A549 cells, phosphorylation or acetylation was induced at most sites by the three DNA damage-inducing agents, but significant differences between agents were observed. IR-induced phosphorylation reached a maximum 2 h after treatment and returned to near pretreatment levels by 72 h; UV light and adriamycin induced a less rapid but more robust and prolonged p53 phosphorylation, which reached a maximum between 8 and 24 h, but persisted (UV) even 96 h after treatment. 
also was observed. Modifications occurred similarly in the HCT116 human colon carcinoma cell line. Analysis of single site mutant p53s indicated clear interdependences between N-terminal phosphorylation sites, which could be classified in four clusters: Ser 6 and Ser 9 ; Ser 9 , Ser 15 , Thr 18 and Ser 20 ; Ser 33 and Ser 37 ; and Ser 46 . We suggest that p53 phosphorylation is regulated through a double cascade involving both the activation of secondary, effector protein kinases as well as intermolecular phosphorylation site interdependencies that check inappropriate p53 inactivation while allowing for signal amplification and the integration of signals from multiple stress pathways.
When normal mammalian cells are exposed to genotoxic agents, including ionizing radiation (IR) 1 or ultraviolet (UV) light, they exhibit a number of responses including a transient inhibition of DNA and RNA synthesis, activation of several kinase-mediated signaling pathways, and the transcriptional induction or repression of several hundred genes, which result in the arrest of cell cycle progression in late G 1 , in S, or in G 2 or in the induction of apoptosis. These responses are mediated, in part, by the p53 tumor suppressor gene, a transcription factor that integrates a variety of stress response signals (reviewed in Refs. [1] [2] [3] [4] ). Exposing cells to genotoxic agents and some non-genotoxic stresses inhibits the degradation of p53 protein through the ubiquitin-mediated pathway and also activates p53 as a DNA-binding, site-specific transcription factor. However, several studies point to important differences in the cellular responses to agents that produce primarily DNA strand breaks (e.g. IR) compared with those that primarily cause base damage such as UV light (reviewed in Refs. 5 and 6). Thus, while p53 protein increases in cells exposed to either IR or UV light, the latter induces much greater p53 transcriptional activity, measured with reporter constructs, than does IR. In fibroblasts and epithelial cells, UV light is a more effective activator of apoptosis than IR (5-7). p53 accumulation and activation also occurs in response to several physiological processes that are not associated with frank DNA damage, including nucleotide deprivation, exposure to microtubule inhibitors, osmotic shock, and senescence potentiated by oncogene activation (see Ref. 1) . p53 accumulation and activation are believed to be regulated through protein phosphorylations and acetylations (reviewed in Refs. 1 and 2). At least 20 sites in the human p53 protein, located primarily in the N-terminal transactivation domains or in the C-terminal regulatory domain proximal or distal to the tetramerization domain, are modified in response to the activation of different stress signaling pathways (1, 2) . For example, at the N terminus of human p53, phosphorylation of Ser 15 , Ser 20 , and Ser 37 , after either IR or UV light, was reported to stabilize p53 (8, 9) ; at the C terminus, phosphorylation of Ser 315 and Ser 392 was implicated in regulating the oligomerization state of p53 (10) and its ability to bind DNA in a sequence-specific manner (11, 12) . Phosphorylation of p53 at N-terminal serines also may enhance interactions with the transcriptional coactivators p300/CBP and PCAF (13) (14) (15) (16) (17) , while acetylation of C-terminal lysines was reported to activate sequence-specific DNA binding and to impair ubiquitination (16, 18) . However, the picture of p53 post-translational modi-* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. ʈ Present Address: Dept. of Medical Biochemistry, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan.
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fications in response to genotoxic and non-genotoxic stresses is incomplete.
To characterize the roles of post-translational modifications in mediating p53 function, we prepared antibodies that recognize 14 of the known p53 specific modification sites only when they have been modified (16, 17, 19, 20) . Here we describe the phosphorylation of p53 at ten different sites in response to two different classes of DNA damaging agents, UV light and IR, in A549 cells, a commonly used line with wild-type p53 that was derived from a human lung carcinoma. We also examined phosphorylation of these sites after treatment with four non-genotoxic agents, ALLN, an inhibitor of ubiquitin-mediated degradation by the 26 S proteasome, taxol and nocodazole, which disrupt microtubules (21, 22) , and N-phosphonacetyl-L-aspartate (PALA), which causes depletion of ribonucleotides without detectable DNA damage (23) . p53 in the HCT116 colon carcinoma cell line, which also expresses wild-type p53, was phosphorylated in essentially an identical manner in response to each agent. p53 acetylation was examined at two sites, Lys 320 and Lys 382 . We furthermore examined the site interdependence of p53 phosphorylation in transient transfection assays by use of mutant p53 expression vectors that had individual serines changed to alanines at most of the reported phosphorylation sites. Together, our results demonstrate the existence of complex signaling cascades that modulate the modification state of the human p53 molecule in cells exposed to stress. (16, 17, 19, 20) . Rabbit polyclonal antibodies specific for mouse p53 phosphorylated at Ser 23 and Ser 37 also have been described (24, 25) . Phosphorylation sitespecific antibodies were affinity-purified from the resulting serum by use of each phosphorylated peptide coupled with Sulfolink (Pierce Chemical Co.). The purified antibodies then were passed through a column coupled with the respective unphosphorylated peptide to deplete antibodies that react with unphosphorylated p53. The specificity of each antibody was confirmed by enzyme-linked immunosorbent assay (ELISA) and dot blot assay using synthetically prepared p53 peptides, and immunoblot assay by probing GST-human p53 expressed in Escherichia coli.
EXPERIMENTAL PROCEDURES
Cell Cultures-A549 (ATCC CCL-185), a human lung carcinoma cell line which express wild-type p53, was obtained from the American Type Culture Collection (Manasas, VA) as was H1299 (ATCC CRL-5803), a human lung carcinoma cell line that is null for both p53 alleles. HCT116, a human colon carcinoma cell line that expresses wild-type p53, was kindly provided by B. Voglstein. A549 and H1299 cells were grown in Dulbecco's modified minimal essential medium (DMEM) and HCT116 cells were in McCoy's 5A medium (Invitrogen Corp., Carlsbad, CA), both supplemented with 10% fetal bovine serum, 100 nM glutamine and penicillin/streptomycin in a humidified atmosphere with 5% CO 2 . Wild-type and p53 S18A/S18A mouse embryonic fibroblasts (MEFs) were prepared from p53 wild-type and p53 S18A/S18A embryos. p53
MEFs were developed from corresponding mutant ES cells using the Hprt-deficient blastocyst complementation approach (25) . All MEFs were cultured in DMEM supplemented with 10% fetal bovine serum, 100 nM glutamine, penicillin/streptomycin, and 50 M ␤-mercaptoethanol in a humidified atmosphere with 5% CO 2 . In the case of PALA treatment, dialyzed fetal bovine serum was used. Treatment of Cell Cultures, Immunoprecipitation, and Western Immunoblot Analysis-Cells were seeded in plastic dishes 24 h prior to treatment and were 60 -70% confluent at the time of treatment. Cultures were exposed to UV light (UV-C, 254 nm) using a Stratagene UV Stratalinker 2400 or to ionizing radiation at a dose rate of 3.2 Gy per minute using a Shepherd Mark I 137 Cs irradiator as described (17) . The proteasome inhibitor ALLN (Calbiochem, La Jolla, CA) was added to cells at a final concentration of 20 M. Adriamycin, taxol, nocodazole (Sigma Chemical Co.) and PALA (NSC224131, obtained from National Cancer Institute, Bethesda, MD) were added to cultures and remained in the cultures until they were harvested. Final concentrations of these agents were chosen after measuring IC 50 values using the WST-1 cell proliferation reagent (Roche Applied Science, Indianapolis, IN) according to the manufacturer's protocol (Table I ). The deacetylase inhibitor trichostatin A (TSA) (WAKO, Osaka, Japan) was added at a final concentration of 5 M 4 h before harvest. Cultures were harvested at the indicated times after treatment and processed for immunoprecipitation and Western immunoblot analyses as described (17) . Anti-human p53 monoclonal antibody DO-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-human p53 polyclonal antibody Ab-7 (Calbiochem), and antimouse p53 polyclonal antibody CM-5 (Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) were obtained as indicated. GST-tagged full-length human p53 protein was purchased from Santa Cruz Biotechnology Inc.
Plasmids, cDNA Constructs, and Transient Transfection-All plasmids and cDNA constructs have been described (17) . The day prior to transfection, 10 6 H1299 cells were seeded in each 10 cm tissue culture dish. On the following day, the cells were transfected with 4 g of the indicated wild-type or mutant p53 expression vector using LipofectAMINE PLUS Reagent (Invitrogen) following the manufacturer's protocol. Cells were exposed to 8 Gy ionizing radiation or 25 J/m 2 UV 18 h after transfection, harvested 2 h or 8 h after exposure to IR or UV light, respectively, then lysed and subjected to immunoprecipitation and Western blot analyses.
RESULTS

Phosphorylation of p53 in A549 Cells in Response to DNA
Damage-inducing Agents-To characterize the post-translational modifications to p53 induced by different DNA damageproducing agents, we prepared individual polyclonal antibodies for different sites that recognize p53 only when it has been modified at that site. The specificity of each antibody was confirmed by ELISA with synthetically prepared p53 peptides or by probing an unmodified human p53 GST-fusion protein expressed in E. coli with purified antibodies. None of the antibodies reacted with the unphosphorylated, wild-type GST-p53 fusion protein ( Fig. 1A and data not shown). We then used these antibodies to follow the phosphorylation of individual sites in response to treatment with three DNA damage-inducing agents, IR, UV light, or adriamycin (ADR) (17) . We also examined acetylation at two sites in the C terminus, Lys 320 and Lys 382 , as previously described (16) . Samples were harvested before treatment and at different times after treatment and then p53 was captured by immunoprecipitation and analyzed by Western immunoblotting (see "Experimental Procedures").
We first examined the dose response of phosphorylation and acetylation to treatment with the three DNA damage-inducing agents. Fig. 1B shows the phosphorylation response after IR for doses between 2 and 32 Gy, and after UV for doses between 7 and 50 J/m 2 at six representative sites: Ser 6 , Ser 15 , Ser 20 , Ser 37 , Ser 46 , and Ser 315 . Also shown is the induction of p53 protein, measured with a p53-specific monoclonal antibody, DO-1. For all sites except perhaps Ser 20 , phosphorylation was induced by 2 h after exposure to as little as 2 Gy IR; however, phosphorylation was significantly greater above 8 Gy. Similar results were seen for UV light at 8 h. Increased phosphorylation was clearly seen at Ser 6 with as little as 7 J/m 2 ; maximum induction of phosphorylation required ϳ25 J/m 2 . Pilot studies showed that 2 h after IR and 8 h after UV were appropriate for assessing phosphorylation responses (see Fig. 2 ). p53 protein accumulation was maximal after exposure to 8 Gy IR or 25 J/m 2 UV; higher doses did not result in significant additional accumulation. Similarly, addition of ADR to 345 nM (0.2 g/ml) was chosen for subsequent analyses (data not shown).
We next examined the time course of modifications at each of 12 p53 sites between 0.5 and 96 h after exposure to 8 Gy IR, 25 J/m 2 UV light, or 345 nM ADR (Fig. 2) . As expected, each treatment induced p53 accumulation, detected with the DO-1 monoclonal antibody. One set of cultures also was treated with 20 M ALLN, which induced p53 accumulation to similar amounts (16) . With ALLN or IR, significant accumulation was observed by one h after treatment; for UV or ADR, significant p53 accumulation clearly was observed by 4 h. Accumulation was persistent after IR, UV, and ADR, and high p53 levels remained even 4 days after exposure. After treatment with ALLN or adriamycin, p53 levels declined between 8 and 24 h after treatment. Fig. 2 shows exposure to 8 Gy IR induced a clear increase in phosphorylation at Ser 6 and Ser 15 by 0.5 h after treatment (17, 19) , and by 2 h maximum phosphorylation was observed at all sites examined except Ser 376 , Ser 378 (data not shown), and Ser 392 . For these three sites, little increase in phosphorylation was observed in response to IR at any time examined. We and others reported increased phosphorylation at Ser 6 and Ser 15 in response to IR as early as 15 min after treatment (16, 17, 19) . In general, IR-induced phosphorylation declined at most sites 24 to 48 h after treatment and had returned to near pretreatment levels by 72 h (Fig. 2) . In contrast, UV light induced a less rapid but more prolonged and robust increase in p53 phosphorylation. Phosphorylation increased at most sites between 2 and 4 h after UV treatment and reached a maximum between 8 and 24 h; at 96 h, significant phosphorylation was still apparent. Phosphorylation in response to ADR resembled the pattern produced by exposure to UV in robustness and timing; note, however, that ADR remained in the culture media until the cells were harvested.
Remarkably, increased phosphorylation was observed at most sites in response to each of the three DNA damageinducing agents; nevertheless, clear differences were observed (Fig. 2) . Phosphorylation at most sites was more strongly in- duced by UV light and ADR than by IR, especially at Ser 33 , Ser 37 , Ser 46 , and Ser 392 . All three agents also promoted acetylation of Lys 382 , while acetylation of Lys 320 was induced most strongly after UV light. The time course of acetylation was similar to phosphorylation but occurred slightly later, consistent with a role for phosphorylation in mediating p53 acetylation (14, 16, 17) .
Four sites, Ser 6 , Ser 33 , Ser 315 , and Ser 392 appeared to be constitutively phosphorylated at a relatively low level in the absence of DNA damage (Fig. 2) . For these sites, phosphorylation increased after adding ALLN in parallel with the increase in p53 protein, but the levels did not approach those observed after treatment with DNA damage-inducing agents. Constitutive phosphorylation was confirmed by showing that the antibodies did not cross-react with a larger amount of an unphosphorylated, human, GST-p53 fusion protein made in E. coli (Fig. 1A) .
Phosphorylation of p53 in A549 and HCT116 Cells in Response to Genotoxic and Non-genotoxic Agents-We next examined HCT116 human colon carcinoma cells (Fig. 3, right) and two normal human fibroblast cell strains to clarify whether the modification patterns seen in A549 cells (Fig. 3, left) were common in other cells after exposure to IR, UV, and ADR. We also examined the effects of three non-genotoxic agents known to activate p53, PALA (Fig. 3, lane 6) , an inhibitor of the L-aspartate transcarbamylase component of the CAD protein that is required for pyrimidine biosynthesis, and two microtubule active drugs, taxol (Fig. 3, lane 7) and nocodazole (Fig. 3,  lane 8 ). Cultures were treated with ADR or these three agents at three times the concentration required for the inhibition of growth by 50% (IC 50 , see Table I) (Fig. 3,  left) , suggesting that the signaling pathways producing these modifications in response to DNA damage probably are common to most cell types. No phosphorylation was observed at Thr 18 in HCT116 cells, and the signals for Ser 9 and Ser 20 were much weaker than for A549 cells.
We next examined modifications at each of the 12 p53 sites after exposure for 24 h to the three non-genotoxic agents PALA, taxol, and nocodazole, each at three times their IC 50 (Fig. 3) . Each induced p53 accumulation to levels similar to those obtained after UV or ADR; however, only a subset of the sites showed strongly enhanced phosphorylation. Phosphorylation was induced at Ser 6 , Ser 33 , Ser 46 , Ser 315 , and Ser 392 in both cell lines by PALA (Fig. 3, lane 6) , taxol (Fig. 3, lane 7) , and nocodazole (Fig. 3, lane 8) to levels equivalent or nearly equivalent to those obtained with UV light or ADR. In contrast, phosphorylation at Ser 9 , Ser 15 and Ser 20 (in A549 cells) was significantly weaker than with UV light or ADR, although some phosphorylation was observed at Ser 15 . No phosphorylation was observed at Thr 18 , nor was acetylation observed at Lys 320 . Lys 382 became acetylated in response to PALA or nocodazole, but acetylation at this site was much weaker than after UV (Fig. 3, lane 4) . Similar results to those shown in , which did not reacted with p53 from A549 cells under the conditions examined. NT, not tested. Shown are representative samples from one of two independent experiments; data for some sites were obtained more than twice to ensure consistency. and MRC-5 normal human lung fibroblasts (data not shown), although in both of these cell lines the modification signals were somewhat weaker than observed after treatment of A549 or HCT116 cells. (20) . These findings suggested the possibility of additional intersite dependences that may reflect complex interactions among signaling cascades leading to the cooperative, extended phosphorylation of the p53 protein after DNA damage.
N-terminal p53 Phosphorylation Site Interdependencies Revealed by Mutational Analysis-Previously
To explore this question, we generated a series of expression vectors for p53 in which each of the serine and threonine residues in the N-terminal transactivation domain of p53 were changed to alanine (17) . We then transfected H1299 lung carcinoma cells, which are deleted for both p53 alleles, with each vector, exposed the cells to IR or not, and processed extracts from each culture for immunoblot analysis with a panel of modification, site-specific antibodies (Fig. 4) . Analysis with a p53-specific polyclonal antibody indicated that wild-type and each mutant p53 were expressed at comparable levels. Some phosphorylation in the absence of IR treatment was expected because the LipofectAMINE PLUS transfection procedure elicits a strong "stress-like" response in human cells (20, 26) . Each of the N-terminal serine and threonine sites in the wild-type p53 protein were phosphorylated well after IR, and no phosphorylation was observed after transfection with empty vector, indicating that the observed phosphorylations were specific to p53 and that the exogenously expressed p53 protein was modified in H1299 cells in the same manner after IR as was the endogenous wild-type p53 protein in the human cell lines analyzed above. As expected, no phosphorylation signal was observed for sites where the amino acid had been changed to alanine (Fig. 4) . As described previously, changing Ser 33 to alanine also blocked phosphorylation of Ser 37 ; however, changing Ser 37 to alanine had no effect on phosphorylation at Ser 33 or at other N-terminal sites. Most striking was the result of substituting alanine for Ser 15 (S15A). This change not only prevented IR-induced phosphorylation at Thr 18 (20) , but it also completely prevented phosphorylation of Ser 9 Table I . TSA (5 M) was added to samples analyzed for acetylation. Sample preparation, immunoprecipitation and Western immunoblotting were as described in the legend to Fig. 2 with the indicated (left) modification-specific antibodies. Data for A549 and HCT116 cells were obtained three times; representative data are shown. Similar results were obtained for WS1 normal human skin fibroblasts and MRC-5 normal human lung fibroblasts (data not shown). specific or phospho-Ser 20 -specific antibodies as well as were the equivalent wild-type phosphorylated peptides. Therefore, the changes of serine to alanine did not prevent recognition by these phospho-specific antibodies. In addition to above two clusters of interdependent sites, changing Ser 6 to alanine blocked phosphorylation at Ser 9 and vice versa without affecting phosphorylation at the other N-terminal sites (Fig. 4) . In contrast, changing either Ser 37 or Ser 46 to alanine had no significant effect on the phosphorylation at other sites, nor did phosphorylation of the C-terminal sites, Ser 315 (17) . Equivalent results to those shown in Fig. 4 were obtained with the Saos-2 human osteosarcoma cell line transfected with the same p53 expression vectors, and essentially the same phosphorylation site dependences also were observed in H1299 cells after exposure to UV light (data not shown). Since the signaling mechanisms responsible for p53 phosphorylation after LipofectAMINE transfection are unknown, the effects of IR and exposure to UV light are not strictly independent, and additional dependences could be revealed when this technical issue is overcome. Our results support, however, the existence of complex DNA damage signaling cascades wherein the final phosphorylation state of p53 not only depends on the sequential activation of specific enzymes, such as been reported for the ATM protein kinase cascade (17, 27) , but also on the specific modification state of the target substrate.
Although p53 post-translational modifications to murine p53 have not been examined as extensively as for human p53, the N-terminal portions of the transactivation domains of human and murine p53, through residue 32, are well conserved, and equivalent residues for Ser 6 , Ser 9 , Ser 15 , Ser 20 , and Thr 18 exist in murine p53. We have developed knock-in mutant murine ES cells and mice in which the endogenous p53 gene was changed so that these cells express p53 in which Ser 18 or Ser 23 , the equivalents of Ser 15 or Ser 20 in human p53, were changed to alanine (25, 28) . To confirm phosphorylation site-interdependence of the p53 N terminus in this physiological setting, we examined p53 phosphorylation in mouse embryonic fibroblasts (MEFs) harboring these mutations after exposure to 345 nM adriamycin with polyclonal antibodies that specifically recognize murine p53 phosphorylated at Ser 18 21 , and Ser 37 were well phosphorylated after adriamycin treatment as reported previously after exposure to UV light or IR (24, 25, 28) . Consistent with the findings reported above for transfected H1299 cells, phosphorylation of Thr 21 , the equivalent to Thr 18 in human p53, was completely abrogated in p53 S18A/S18A MEFs, while Ser 37 remained phosphorylated. Likewise, phosphorylation of Thr 21 was blocked in p53 S23A/Ϫ MEFs. Analysis of the phosphorylation state of Ser 23 was not informative, possibly because phosphorylation levels were too low and/or because of the relatively low affinity of our phospho-Ser 23 -specific antibody. Thus, although limited, these observations are consistent with the Ser 15 cluster of phosphorylation site interdependencies observed in human cells.
DISCUSSION
Circumstantial evidence accumulated over the past ϳ10 years suggests that p53 is stabilized and activated in response to DNA damage and other cellular stresses through post-translational modifications to the p53 protein itself, as well as to other proteins with which it interacts. At least seventeen sites in the human p53 protein are modified in vivo in response to the activation of different stress signaling pathways through phosphorylation or acetylation (1, 2 (29, 30) , but the significance of modifications to these sites in vivo has not been established. Thus, while a reasonably complete picture of the types and sites of posttranslational modifications that p53 can undergo has emerged, it has been difficult to elucidate connections with specific signal transduction pathways and to show causal effects for specific post-translational modifications. Here we provide, for the first time, a relatively comprehensive picture in two human cell lines of the post-translational modifications to p53 in response to several genotoxic and non-genotoxic agents. This comparison of the responses at multiple sites to different agents represents an important step in the elucidation of the signaling pathways that regulate p53 because currently it is not possible to obtain FIG. 4 . Intramolecular phosphorylation site dependences at the N terminus of human p53 after exposure to ionizing radiation (IR). H1299 cells were transiently transfected with vector alone, or with wild-type or mutant p53 expression vectors. Cells were exposed to 8 Gy ␥-rays and then harvested 2 h after IR exposure. Sample preparation, immunoprecipitation and Western blotting were as described in the legend to Fig. 2 except that the p53-specific polyclonal antibody Ab-7 was used instead of DO-1 to detect the expression levels of p53 in transfected cells. quantitative information for most modification sites, which impedes the interpretation of data from reports that have examined only one or two sites using the currently available commercial p53 phospho-or acetylation-specific antibodies.
The development of phosphorylation site-specific antibodies was critical for the study of p53 because, previously, the only practical way of detecting p53 phosphorylation was the use of radioactive labels that themselves cause DNA damage, thus making the interpretation of such experiments problematic. Fig. 2 shows the response of human p53 at 14 different sites to three DNA damage-inducing agents. Our antibodies that react specifically with peptides phosphorylated at Ser 376 or Ser 378 , which were reported to be constitutively phosphorylated (31) (37, 38) . A striking observation is that modification of p53 at most sites is enhanced after cells are exposed to the DNA damageinducing agents examined (Figs. 2 and 3 ). While several protein kinases have been reported to be activated in cells exposed to genotoxic substances, this observation raises the possibility that increased phosphorylation may result from the DNA-damage induced inhibition of p53 dephosphorylation as well as from the activation of specific protein kinases. Although p53 modulates the expression of both the Wip1 (PPM1D) (39) and cdc25C phosphatases (40) , and the PTEN phosphatase was reported to regulate p53 protein levels and transcriptional activity (41), little is known about the effects of stress pathway signaling on protein phosphatase activities. Fig. 2 also reveals a few clear differences between the responses to the three genotoxic agents examined in this study. Phosphorylation increase more rapidly after exposure to IR than to UV light; in contrast, the response to UV light or ADR, while generally was less rapid, was more robust and was retained longer. Phosphorylation in response to IR increased up to a dose of ϳ8 Gy, which produces about 300 double-strand breaks per cell. Phosphorylation increased in response to UV light up to ϳ25 J/m 2 , which produces about three-quarter of a million DNA photoproducts per cell. While cells respond to these genotoxic agents at much lower doses, our observations show that higher cytotoxic doses are required to maintain p53 phosphorylation at maximal levels, perhaps as a consequence of sustained DNA damage that cannot be readily repaired.
Differences in modifications also were observed at individual sites for the different genotoxic agents. In the N-terminal region, phosphorylation of Thr 18 was stronger in response to IR and ADR than to UV light (Fig. 3) , while phosphorylation at Ser 33 , Ser 37 , and Ser 46 was induced more strongly after UV light or ADR than after IR. At the C terminus, phosphorylation was induced at Ser 315 by all three agents, while phosphorylation at Ser 392 was induced by UV light or ADR, but not by IR (Fig. 2) (42, 43) . Lys 382 was acetylated after exposure of A549 cells to all three agents, but more robustly after UV light or ADR, consistent with the more robust induction of phosphorylation at Ser 15 and other N-terminal sites by these agents (14, 17) . Likewise, Lys 320 was acetylated robustly after UV light or ADR, but not after IR. Although some differences between cell lines have been observed (e.g. Fig. 3 15 phosphorylation was significantly increased in human fibroblasts undergoing replicative senescence (46), but not in those undergoing Ras-induced premature senescence (47) .
Exposure to non-genotoxic agents induced phosphorylation of a subset of those sites phosphorylated in response to genotoxins or, in the case of ALLN, no phosphorylation at all. ALLN is an inhibitor of degradation by the 26 S proteasome and induces p53 accumulation to levels comparable to those induced by DNA damage but does not activate p53-mediated transcription (16) . While treatment of cells with ALLN did not induce phosphorylation, a low level of constitutive phosphorylation at four sites, Ser 6 , Ser 33 , Ser 315 , and Ser 392 , was revealed that increased in parallel with p53 levels (Fig. 2) . Taxol (Paclitaxel), one of the newer chemotherapy drugs commonly used to treat ovarian, breast, and head and neck cancers, inhibits microtubule depolymerization and has been reported to activate p53-dependent transcription and its phosphorylation at several sites. Damia et al. (22) reported that taxol induced p53 phosphorylation at Ser 20 but not Ser 15 in HCT116 cells, while Stewart et al. (21) found that both taxol and nocodazole induced a modest increase in p53 phosphorylation at multiple sites, including Ser 15 , in HCT116 and RKO cells, but not in normal human dermal fibroblasts. In general agreement with these investigators, we observed modest phosphorylation of Ser 15 in A549 or HCT116 cells in response to PALA, taxol, or nocodazole, and no significant phosphorylation at Ser20 (Fig. 3) . However, in response to these non-genotoxic agents, we also ob- 
